반응 #2014341

ord-57a3be0337ba4b55be28e7ccf108a999

반응 조건

상세 조건
See reaction.notes.procedure_details.

후처리

  1. 1
    기타The volatiles were removed in vacuo
  2. 2
    workup.DISSOLUTIONThe residue was redissolved in acetonitrile (5 mL)
  3. 3
    기타evaporated again
  4. 4
    기타to afford 17 mg of the crude product as a yellow solid
  5. 5
    기타The crude product was purified via reverse phase HPLC

실험 절차

(S)-tert-butyl 4-(3-(3-chloro-6-hydroxyphenyl)phenyl)-1,4-dimethyl-6-oxo-tetrahydropyrimidin-2(1H)-ylidenecarbamate (CF3; R1═R6=Me, R21=3-chloro-6-hydroxyphenyl) (23 mg, 0.05 mmol) was treated with 1 mL of 30% TFA/CH2Cl2 at RT for 30 min. The volatiles were removed in vacuo. The residue was redissolved in acetonitrile (5 mL) and evaporated again to afford 17 mg of the crude product as a yellow solid. The crude product was purified via reverse phase HPLC to provide 10 mg (60%) of (S)-6-(3-(3-chloro-6-hydroxy-phenyl)phenyl)-6-ethyl-2-imino-3-methyl-tetrahydropyrimidin-4(1H)-one (CF4; R1═R6=Me, R21=3-chloro-6-hydroxyphenyl) as a white solid. 1HNMR (CDCl3, 300 MHz): 11.4 (br s, 1H), 7.6-4.25 (m, 3H), 7.24-6.84 (m, 3H), 3.68 (brs, 1H), 5.18 (brs, 1H), 3.39 (d, J=16.1 Hz, 1H), 3.20 (s, 3H), 2.95 (d, J=15.8 Hz, 1H), 1.74 (s, 3H). MS (ESI): MH+=344.1. HPLC (A) Rt=5.07 min.

출처

DOI: 10.6084/m9.figshare.5104873.v1특허: US08183252B2uspto-grants-2012_05